Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone
© Zurenko et al.; licensee BioMed Central Ltd. 2014
Received: 27 June 2014
Accepted: 5 September 2014
Published: 20 September 2014
Tedizolid is a novel oxazolidinone antibacterial with potent activity against a wide range of Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. Although tedizolid is approved by the US Food and Drug Administration (FDA) for treatment of patients with acute bacterial skin and skin structure infection, commercial susceptibility testing products for tedizolid are not currently available. This study evaluated the usefulness of applying linezolid susceptibility test results as a surrogate for predicting susceptibility to tedizolid in clinically significant Gram-positive pathogens.
Gram-positive isolates (N=10,702) were obtained from annual surveillance programs conducted between 2009 and 2012, from 3 tedizolid clinical trials, and from a preclinical study of the antibacterial activity of tedizolid. Susceptibility testing of linezolid and tedizolid was performed using the reference broth microdilution method in accordance with Clinical and Laboratory Standards Institute methods.
The minimum inhibitory concentration (MIC) distribution for tedizolid and linezolid against this set of isolates was consistent with that of previous reports. Scatter plot analysis of relevant subsets of organisms was performed and showed high categorical agreement between linezolid and tedizolid MIC results (>99% for staphylococci and streptococci; >98% for enterococci). Very major error rates (ie, tedizolid false-susceptible errors) were very low and within acceptable limits for a surrogate agent: S. aureus and other staphylococcal species, 0%; Enterococcus spp, 0.2%; and Streptococcus spp, 0%.
High categorical agreement between MIC values for tedizolid and linezolid and low very major error rates were shown for all organism groups tested, supporting the use of linezolid as a reliable surrogate for tedizolid susceptibility testing.
Tedizolid phosphate is a novel oxazolidinone prodrug antibacterial that is rapidly converted by endogenous phosphatases to the active moiety tedizolid. Tedizolid has potent activity against a wide range of Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) -. The efficacy of tedizolid phosphate 200mg once daily for 6days was shown to be noninferior to linezolid 600 mg twice daily for 10 days in each of 2 phase 3 clinical trials in patients with acute bacterial skin and skin structure infection (ABSSSI) ,. In June 2014, the US Food and Drug Administration (FDA) approved tedizolid phosphate for treatment of patients with ABSSSI caused by certain susceptible Gram-positive pathogens .
For new antimicrobial agents, availability of commercial susceptibility testing products always lags behind drug approval by regulatory authorities because manufacturers of susceptibility testing products cannot seek FDA clearance to market their products until after drug approval. To facilitate antimicrobial susceptibility testing by clinical laboratories for a recently approved antimicrobial agent, an established agent from the same or similar class is often used as a surrogate to predict the susceptibility of clinical isolates to the new agent. Examples include the use of ceftriaxone for cefpodoxime ; carbapenem and third- and fourth-generation cephalosporins for ceftaroline ; vancomycin or teicoplanin for dalbavancin ; levofloxacin for gatifloxacin, moxifloxacin, and gemifloxacin ; and fluconazole or voriconazole for posaconazole .
Linezolid, the only other commercially available oxazolidinone, was first approved in the United States in 2000 and is now widely available in multiple commercial susceptibility testing products. We evaluated the usefulness of linezolid as a surrogate agent for predicting the susceptibility of clinically significant Gram-positive pathogens to tedizolid.
Material and methods
Sources for bacterial strains
A total of 10,702 Gram-positive isolates were obtained from annual surveillance programs, from 3 clinical trials of tedizolid for treatment of ABSSSI, and from a preclinical study of tedizolid activity that included linezolid-resistant isolates. The surveillance isolates included 9022 Gram-positive clinical isolates collected from sites in the United States, Belgium, Czech Republic, France, Germany, Hungary, Italy, Spain, Sweden, and United Kingdom from 2009 through 2012. A total of 937 isolates were collected between 2008 and 2013 from a US-based phase 2 and from 2 multinational phase 3 clinical trials of tedizolid (NCT01519778, NCT0117022, and NCT01421511). An additional 743 isolates were collected in the United States as part of a preclinical study to evaluate the antibacterial activity of tedizolid . Overall, the isolates included in this study were composed of the following groupings: S. aureus (n=7187), staphylococci other than S. aureus (n=674), Enterococcus spp (n=1241), and Streptococcus spp (n=1600).
Susceptibility testing was performed using the reference broth microdilution method in accordance with the guidelines of the Clinical and Laboratory Standards Institute (CLSI) . Tedizolid was supplied by Cubist Pharmaceuticals (San Diego, CA); ThermoFisher Scientific (Cleveland, OH) produced the broth microdilution panels for the annual surveillance programs and the clinical trials; Clinical Microbiology Institute (Wilsonville, OR) produced the broth microdilution panels for the preclinical study . Assay performance was monitored using CLSI-recommended quality control strains S. aureus ATCC 29213, Enterococcus faecalis ATCC 29212, and Streptococcus pneumoniae ATCC 49619.
For select organism groupings, the minimum inhibitory concentration (MIC) results for tedizolid were directly compared with those for linezolid using scatter plots. The FDA approved the following tedizolid breakpoints: ≤0.5 μg/ml (susceptible), 1 μg/ml (intermediate), and ≥2 μg/ml (resistant) for S. aureus (including MRSA isolates); ≤0.5 μg/ml (susceptible) for Streptococcus pyogenes, Streptococcus agalactiae, and E. faecalis; and ≤0.25 μg/ml (susceptible) for Streptococcus anginosus group isolates (ie, S. anginosus, S. intermedius, and S. constellatus) . For the analyses presented in the current study, the following tedizolid breakpoints were applied: ≤0.5 μg/ml (susceptible), 1 μg/ml (intermediate), and ≥2 μg/ml (resistant) for staphylococci; ≤0.5 μg/ml (susceptible) and ≥1 μg/ml (nonsusceptible) for streptococci and enterococci; and ≤0.25 μg/ml (susceptible) and ≥0.5 μg/ml (nonsusceptible) for analysis of only the S. anginosus group isolates. Current CLSI breakpoints were applied for linezolid .
The definitions of errors in these analyses were (1) very major error (ie, a false-susceptible error in which a susceptible result was obtained for linezolid and a resistant [or nonsusceptible] result was obtained for tedizolid); (2) major error (ie, a false-resistant error in which a resistant [or nonsusceptible] result was obtained for linezolid and a susceptible result was obtained for tedizolid); and (3) minor error (ie, result for one of the agents was intermediate and the other agent was susceptible, nonsusceptible, or resistant) . Error rates were calculated separately for each organism grouping using the total number of isolates in the respective grouping as the denominator.
Cumulative inhibition at MIC values by organism grouping and antimicrobial agent
Organism grouping (no. tested)
Cumulative number (%) of isolates inhibited at MIC value (μg/ml)
S. aureus (7187)
Staphylococcal species (non-S. aureus)b (674)
Enterococcus spp. (1241)
Streptococcus spp. (1600)
Streptococcus anginosus groupc (91)
Linezolid as a surrogate for tedizolid susceptibility when testing S. aureus isolates
Linezolid as a surrogate for tedizolid susceptibility when testing staphylococcal isolates other than S. aureus
Linezolid as a surrogate for tedizolid susceptibility when testing enterococcal isolates
Linezolid as a surrogate candidate for streptococci
Tedizolid is a novel oxazolidinone approved by the FDA for management of ABSSSI caused by certain susceptible Gram-positive pathogens, and is in further clinical development for management of nosocomial pneumonia. Tedizolid represents a potentially valuable therapeutic addition to the antimicrobial agents currently used for management of ABSSSI; however, FDA-approved commercial products for tedizolid susceptibility testing are currently unavailable. This analysis demonstrated that linezolid, the only oxazolidinone available in commercial susceptibility testing products , can serve as a surrogate agent to predict tedizolid susceptibility of clinically relevant Gram-positive pathogens.
For all organism groupings tested (S. aureus, staphylococci other than S. aureus, Enterococcus spp, Streptococcus spp, and S. anginosus group), linezolid susceptibility was highly predictive of tedizolid susceptibility. For all pathogen groups, the categorical agreement between test results for tedizolid and linezolid was >98%, and rates of very major and major errors were well within the CLSI limits of acceptability (ie, very major and major error rates of ≤1.5% and ≤3%, respectively) . Recommendations from previous studies indicate that absolute categorical agreement rates of ≥90% are essential and rates of ≥95% are preferred ,. In this study, the risk for very major error where an isolate would be reported as susceptible despite being resistant or nonsusceptible was rare and was highest for Enterococcus spp, which had a reported very major error rate of only 0.2%. The FDA-approved breakpoints for tedizolid were derived from MIC population distributions, pharmacokinetic/pharmacodynamics information, Monte Carlo simulations, and clinical and microbiological outcome data from the ABSSSI clinical program.
The main mechanisms for linezolid resistance consist of mutations in chromosomal genes encoding 23S ribosomal RNA and ribosomal proteins L3 and L4, or the presence of the plasmid-borne cfr gene. Although tedizolid MIC values are affected by chromosomal mutations, tedizolid has been shown to retain antimicrobial activity against strains with the cfr gene -. When linezolid is used as a surrogate testing agent for tedizolid, cfr-positive isolates will likely result in major errors (false resistance or false nonsusceptible). In these rare instances, the major errors should not adversely affect patient care because a laboratory result of resistant or nonsusceptible to tedizolid should preclude the use of the agent in these situations.
Clinical laboratories have successfully used a class representative to predict susceptibility to other agents in the same class as a practical alternative when specific susceptibility testing products are unavailable -. Given the lack of such products for tedizolid, this approach provides a useful strategy to assist in the appropriate therapeutic use of tedizolid against clinically important Gram-positive pathogens. As commercial tedizolid susceptibility products become available, they could rapidly replace the interim use of linezolid as the surrogate testing agent.
This analysis showed that, for all Gram-positive pathogen groups tested, there was high categorical agreement between tedizolid and linezolid susceptibility results, and rates of very major errors and major errors were well within acceptable limits. These findings show that linezolid can be used as a reliable surrogate to predict susceptibility testing results for tedizolid against clinically relevant Gram-positive pathogens. Consideration should be given to the use of linezolid as a surrogate so susceptibility testing results for tedizolid can be made rapidly available to health care providers.
All authors had access to the complete data set, read and approved the final manuscript, and meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship.
This study was funded by Cubist Pharmaceuticals. Editorial assistance was provided by ApotheCom ScopeMedical and funded by Cubist Pharmaceuticals. The authors wish to acknowledge Dan Sahm and the Eurofins Medinet team for contributing the data from the annual surveillance programs, Steve Brown and Maria Traczewski from Clinical Microbiology Institute for contributing the data from the preclinical study of tedizolid activity, and Sam Bouchillon of IHMA for assistance with database development.
- Brown SD, Traczewski MM: Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges. Antimicrob Agents Chemother 2010, 54: 2063-2069. 10.1128/AAC.01569-09PubMedPubMed CentralView ArticleGoogle Scholar
- Prokocimer P, Bien P, Deanda C, Pillar CM, Bartizal K: In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2012, 56: 4608-4613. 10.1128/AAC.00458-12PubMedPubMed CentralView ArticleGoogle Scholar
- Thomson KS, Goering RV: Activity of tedizolid (TR-700) against well-characterized methicillin-resistant Staphylococcus aureus strains of diverse epidemiological origins. Antimicrob Agents Chemother 2013, 57: 2892-2895. 10.1128/AAC.00274-13PubMedPubMed CentralView ArticleGoogle Scholar
- Locke JB, Zurenko GE, Shaw KJ, Bartizal K: Tedizolid for the management of human infections: in vitro characteristics. Clin Infect Dis 2014,58(Suppl 1):S35-S42. 10.1093/cid/cit616PubMedView ArticleGoogle Scholar
- Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P: Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2014, June 5 [Epub ahead of print].Google Scholar
- Prokocimer P, De Anda C, Fang E, Mehra P, Das A: Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 2013, 309: 559-569. 10.1001/jama.2013.241PubMedView ArticleGoogle Scholar
- Prescribing information. Cubist Pharmaceuticals, Lexington, MA; 2014.Google Scholar
- Jones RN, Zurenko GE: Prediction of bacterial susceptibility to cefpodoxime by using the ceftriaxone minimum inhibitory concentration result. Diagn Microbiol Infect Dis 1993, 17: 313-316. 10.1016/0732-8893(93)90041-5PubMedView ArticleGoogle Scholar
- Jones RN, Flamm RK, Sader HS, Stilwell MG: Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate beta-lactam markers to predict ceftaroline activity against clinically indicated species. Diagn Microbiol Infect Dis 2013, 75: 89-93. 10.1016/j.diagmicrobio.2012.08.022PubMedView ArticleGoogle Scholar
- Jones RN, Sader HS, Fritsche TR, Hogan PA, Sheehan DJ: Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program. J Clin Microbiol 2006, 44: 2622-2625. 10.1128/JCM.00576-06PubMedPubMed CentralView ArticleGoogle Scholar
- Sader HS, Koeth LM, Poupard JA, Jones RN: Interpretive categorical accuracy of fluoroquinolone reference broth microdilution MIC results when testing Streptococcus pneumoniae : selection of a surrogate testing agent. Diagn Microbiol Infect Dis 2008, 62: 460-463. 10.1016/j.diagmicrobio.2008.08.020PubMedView ArticleGoogle Scholar
- Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ: Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J Clin Microbiol 2008, 46: 551-559. 10.1128/JCM.01952-07PubMedPubMed CentralView ArticleGoogle Scholar
- Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard. CLSI, Wayne, PA; 2012.Google Scholar
- Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement (document M100-S24). CLSI, Wayne, PA; 2014.Google Scholar
- Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters; Approved Guideline. (document M23-A3). CLSI, Wayne, PA; 2008.Google Scholar
- Shaw KJ, Barbachyn MR: The oxazolidinones: past, present, and future. Ann N Y Acad Sci 2011, 1241: 48-70. 10.1111/j.1749-6632.2011.06330.xPubMedView ArticleGoogle Scholar
- Shaw KJ, Poppe S, Schaadt R, Brown-Driver V, Finn J, Pillar CM, Shinabarger D, Zurenko G: In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother 2008, 52: 4442-4447. 10.1128/AAC.00859-08PubMedPubMed CentralView ArticleGoogle Scholar
- Livermore DM, Mushtaq S, Warner M, Woodford N: Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci. J Antimicrob Chemother 2009, 63: 713-715. 10.1093/jac/dkp002PubMedView ArticleGoogle Scholar
- Locke JB, Finn J, Hilgers M, Morales G, Rahawi S, CK G, Picazo JJ, Im W, Shaw KJ, Stein JL: Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. Antimicrob Agents Chemother 2010, 54: 5337-5343. 10.1128/AAC.00663-10PubMedPubMed CentralView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.